Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neurexan is a multi-component homeopathic medicinal product developed by Biologische Heilmittel Heel GmbH, primarily indicated for the treatment of nervous restlessness, stress-related symptoms, and sleep disturbances such as short-term insomnia. The formulation consists of four active ingredients: *Passiflora incarnata* (passionflower), *Avena sativa* (oats), *Coffea arabica* (coffee), and *Zincum isovalerianicum* (zinc valerate). Neurexan is designed to modulate the stress response by stabilizing the hypothalamic-pituitary-adrenal (HPA) axis and reducing stress-induced cortisol levels. Unlike conventional hypnotics, it aims to improve sleep efficiency and daytime performance without causing sedation, dependency, or morning grogginess. Clinical research, including Phase 2 trials, has utilized polysomnography (PSG) and electroencephalography (EEG) to evaluate its efficacy in addressing insomnia and stress-induced physiological changes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neurexan.